Medicine for treating thrombocytopenic purpura and preparation method thereof

A platelet and drug technology, applied in drug combinations, blood diseases, medical raw materials derived from ferns/filamentous plants, etc. Xing's syndrome and other problems, to achieve the effect of promoting platelet aggregation, reducing the amount and frequency of drug use, and increasing platelet count

Inactive Publication Date: 2009-09-16
GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] 1. Long-term repeated administration is required, and the side effects are quite large, causing complications in the digestive system and cardiovascular system, and even inducing and aggravating infection
[0006] 2. Prednisone drugs clinically used to treat thrombocytopenic purpura can easily cause side effects such as Cushing's syndrome, virilization, high blood pressure, and weakened body resistance; immunosuppressant cyclophosphamide drugs can inhibit Hematopoietic function of bone marrow; Danazol drugs have side effects of damage to liver function
[0007] 3. The curative effect is not good, and 25% of the patients' condition cannot be controlled
[0008] Although there are some related Chinese patent medicines for treatment, patients still have to rely on western medicines because the effect is not very obvious.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating thrombocytopenic purpura and preparation method thereof
  • Medicine for treating thrombocytopenic purpura and preparation method thereof
  • Medicine for treating thrombocytopenic purpura and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Jiangnan Selaginella preparation consists of main agent and auxiliary materials, and its components are 50 parts by weight of main agent, 53 parts of auxiliary materials, the main agent is Jiangnan Selaginella dry paste powder 50, starch in auxiliary materials is 25, aluminum hydroxide 8, hydroxyl Promellose 8, Carboxymethyl Starch Sodium 10, Magnesium Stearate 2.

[0035] The preparation method of preparing tablet medicine is as follows:

[0036] (a) Get 3900g of Selaginella chinensis medical material, remove impurity after it is washed, pass through inspection;

[0037] (b) adding 10 times of water and decocting for 3 hours, filtering off the decoction, and concentrating the filtrate to a clear paste with a relative density of 1.05;

[0038] (c) drying under reduced pressure, pulverizing to obtain 190g of Selaginella chinensis dry cream powder;

[0039] (d) Add 30.6g of aluminum hydroxide, 30.4g of hydroxypropyl cellulose, 95g of starch, and 38g of carboxymethyl sta...

Embodiment 2

[0043] Jiangnan Selaginella preparation is made up of main agent and auxiliary material, and its each component is main agent 85% by weight, auxiliary material 15%, main agent is Jiangnan Selaginella dry paste powder 85%, auxiliary material Arabic gum 4, starch 4, aluminum hydroxide are 2. Sodium carboxymethyl starch 2, carmellose 2.5, talcum powder 0.5.

[0044] The preparation method of preparing tablet medicine is as follows:

[0045] (a) Get 6700g of Selaginella chinensis medical material, remove impurity after it is washed, pass the inspection;

[0046] (b) add 20 times of water and decoct for 2 hours, filter the decoction, and concentrate the filtrate to a clear paste with a relative density of 1.25;

[0047] (c) drying under reduced pressure, pulverizing to obtain 320g of Selaginella jiangnan dry cream powder;

[0048] (d) Add 15.2g of gum arabic, 7.53g of aluminum hydroxide, 9.4g of carmellose, and 7.53g of sodium starch glycolate to the dry paste powder of Selaginel...

Embodiment 3

[0052] Jiangnan Selaginella preparation is composed of main agent and auxiliary materials, and its components are 68 parts by weight as main agent, 33.5 parts of auxiliary materials. 8. Hypromellose 5. Magnesium stearate 0.5.

[0053] The preparation method of preparing tablet medicine is as follows:

[0054] (a) Get 4300g of Selaginella chinensis medical material, remove impurity after it is cleaned, be cut into small sections after passing the inspection;

[0055] (b) add 30 times of water and decoct for 1 hour, filter out the decoction, process the filter residue once more according to the aforementioned conditions, combine the filtrate, and concentrate the filtrate to a clear paste with a relative density of 1.28;

[0056] (c) dried under reduced pressure, pulverized to obtain 217.6g of Selaginella chinensis dry cream powder;

[0057](d) Add 32.3g of mannitol, 26.8g of starch, 25.6g of hydroxypropyl cellulose, and 16.4g of carmellose to the dry paste powder of Selaginell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine for treating thrombocytopenic purpura and a preparation method thereof, belonging to the field of traditional Chinese medicines. The medicine comprises 30-90 weight parts of dry extract powder of selaginella moellendorfii and 10-70 weight parts of pharmaceutical adjuvant and is prepared into tablets, capsules, granules and pills by various methods. The preparation process is simple, the cost is low and the prepared preparations have excellent performance and stable quality and are convenient for the patients to take. Clinical trials show that the medicine can achieve better clinical results and has no obvious side effects when being applied to treating thrombocytopenic purpura and other hemorrhagic diseases.

Description

technical field [0001] The invention relates to a medicine for treating thrombocytopenic purpura, in particular to a formulation prepared from Selaginella chinensis medicinal material, and also relates to a preparation method of the medicine. Background technique [0002] Thrombocytopenic purpura is a common hemorrhagic disease, accounting for about 70% of hemorrhagic diseases, and has an increasing trend year by year. The first onset is usually under the age of 30. The bleeding is severe at the onset, causing extensive skin and mucous membrane blood spots or ecchymosis or even subcutaneous hematoma. Long-term repeated bleeding can cause anemia and symptoms such as low fever, fatigue, and dizziness. [0003] The cause of thrombocytopenic purpura is that the presence of platelet-associated antibodies in the patient's microcirculatory system increases the destruction of platelets in macrophages and decreases peripheral platelets, resulting in a series of bleeding symptoms. Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/11A61P7/04
Inventor 吴振华郑丽真卢丹许淑文邓淑渊许春江叶放
Owner GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap